Argus upgraded shares of Mylan (NASDAQ:MYL) from a hold rating to a buy rating in a report issued on Thursday, Marketbeat.com reports. They currently have $42.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Mizuho reiterated a buy rating and set a $54.00 price target on shares of Mylan in a research report on Wednesday, August 8th. Citigroup reduced their price target on shares of Mylan from $50.00 to $48.00 and set a buy rating on the stock in a research report on Thursday, August 9th. Bank of America raised shares of Mylan from a neutral rating to a buy rating and dropped their price objective for the stock from $44.00 to $42.00 in a research note on Tuesday, November 6th. Royal Bank of Canada dropped their price objective on shares of Mylan from $51.00 to $50.00 and set a buy rating on the stock in a research note on Tuesday, November 6th. Finally, Wells Fargo & Co raised shares of Mylan from a market perform rating to a buy rating and set a $40.00 price objective on the stock in a research note on Tuesday, November 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $46.56.

Shares of NASDAQ MYL opened at $34.92 on Thursday. Mylan has a 1 year low of $30.33 and a 1 year high of $47.82. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.77 and a current ratio of 1.26. The stock has a market cap of $18.01 billion, a P/E ratio of 7.66, a P/E/G ratio of 1.15 and a beta of 1.53.

Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, November 5th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.06. Mylan had a net margin of 4.71% and a return on equity of 19.39%. The company had revenue of $2.86 billion for the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter in the previous year, the company earned $1.10 earnings per share. Mylan’s quarterly revenue was down 4.2% on a year-over-year basis. As a group, equities analysts predict that Mylan will post 4.66 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. First Mercantile Trust Co. bought a new position in shares of Mylan in the second quarter worth approximately $121,000. Stratos Wealth Partners LTD. bought a new position in shares of Mylan in the third quarter worth approximately $183,000. FTB Advisors Inc. bought a new position in shares of Mylan in the second quarter worth approximately $188,000. Reilly Financial Advisors LLC lifted its stake in shares of Mylan by 69.4% in the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock worth $191,000 after buying an additional 2,137 shares in the last quarter. Finally, BB&T Corp bought a new position in shares of Mylan in the third quarter worth approximately $202,000. Hedge funds and other institutional investors own 81.91% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Further Reading: Marijuana Stocks Investing Considerations

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.